ls from within: the DNA damage induced NF kappaB response. Cell Death Differ. 2006, 13, 773 784. 153. Karin, M, Greten, F.R. NF kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 2005, 5, 749 759. 154. Bonizzi, G, Karin, M. The two NF kappaB activation pathways and their role in innate and adaptive immunity. Dasatinib Bcr-Abl inhibitor Trends Immunol. 2004, 25, 280 288. 155. Xie, K. Interleukin 8 and human cancer biology. Cytokine Growth Factor Rev. 2001, 12, 375 391. 156. Garg, A, Aggarwal, B.B. Nuclear transcription factor kappaB as a target for cancer drug development. Leukemia 2002, 16, 1053 1068. 157. Nathan, C. Points of control in inflammation. Nature 2002, 420, 846 852. 158. Balkwill, F, Charles, K.A, Mantovani, A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease.
Cancer Cell 2005, 7, 211 217. 159. Ulrich, C.M, Potter, J.D. Testing for colon neoplasia susceptibility variants at the human Cox2 locus. J. Natl. Cancer Inst. 2001, 93, 1572 1574. 160. Suh, N, Wang, Y, Honda, Irinotecan T, Gribble, G.W, Dmitrovsky, E, Hickey, W.F, Maue, R.A, Place, A.E, Porter, D.M, Spinella, M.J, Williams, C.R, Wu, G, Dannenberg, A.J, Flanders, K.C, Letterio, J.J, Mangelsdorf, D.J, Nathan, C.F, Nguyen, L, Porter, W.W, Ren, R.F, Roberts, Toxins 2010, 2 2462 A.B, Roche, N.S, Subbaramaiah, K, Sporn, M.B. A novel synthetic oleanane triterpenoid, 2 cyano 3,12 dioxoolean 1,9 dien 28 oic acid, with potent differentiating, antiproliferative, and anti inflammatory activity. Cancer Res. 1999, 59, 336 341. 161. Suh, N, Roberts, A.
B, Birkey Reffey, S, Miyazono, K, Itoh, S, ten Dijke, P, Heiss, E.H, Place, A.E, Risingsong, R, Williams, C.R, Honda, T, Gribble, G.W, Sporn, M.B. Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling. Cancer Res. 2003, 63, 1371 1376. 162. Suh, W.S, Kim, Y.S, Schimmer, A.D, Kitada, S, Minden, M, Andreeff, M, Suh, N, Sporn, M, Reed, J.C. Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL. Leukemia 2003, 17, 2122 2129. 163. Ahmad, R, Raina, D, Meyer, C, Kharbanda, S, Kufe, D. Triterpenoid CDDO Me blocks the NF kappaB pathway by direct inhibition of IKKbeta on Cys 179. J. Biol. Chem. 2006, 281, 35764 35769. 164. Yore, M.M, Liby, K.T, Honda, T, Gribble, G.W, Sporn, M.B.
The synthetic triterpenoid 1 imidazole blocks nuclear factor kappaB activation through direct inhibition of IkappaB kinase beta. Mol. Cancer Ther. 2006, 5, 3232 3239. 165. Couch, R.D, Browning, R.G, Honda, T, Gribble, G.W, Wright, D.L, Sporn, M.B, Anderson, A.C. Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: implications for a molecular mechanism of action. Bioorg. Med. Chem. Lett 2005, 15, 2215 2219. 166. Haridas, V, Kim, S.O, Nishimura, G, Hausladen, A, Stamler, J.S, Gutterman, J.U. Avicinylation : a protein modification that can regulate the response to oxidative and nitrosative stress. Proc. Natl. Acad. Sci. USA 2005, 102, 10088 10093. 167. Deeb, D, Gao, X, Jiang, H, Dulchavsky, S.A, Gautam, S.C.
Oleanane triterpenoid CDDO Me inhibits growth and induces apoptosis in prostate cancer cells by independently targeting pro survival Akt and mTOR. Prostate 2009, 69, 851 860. 168. Dirsch, V.M, Kiemer, A.K, Wagner, H, Vollmar, A.M. The triterpenoid quinonemethide pristimerin inhibits induction of inducible nitric oxide synthase in murine macrophages. Eur. J. Pharmacol. 1997, 336, 211 217. 169. Brunelleschi, S, Bardelli, C, Amoruso, A, Gunella, G, Ieri, F, Romani, A, Malorni, W, Franconi, F. Minor polar compounds extra virgin olive oil extract inhibits NF kappa B translocation in human monocyte/macrophages. Pharmacol. Res. 2007, 56, 542 549. 170. Tundis, R, Bonesi, M, Degui